Sugi Predict

Sugi Predict / Compounds / SCHEMBL1401544

SCHEMBL1401544

SCHEMBL1401544

COC(=O)c1ccc(CO)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ PPARG P37231 1/20 0.53
▸ NCOA2 Q15596 1/20 0.53
▸ NCOA1 Q15788 1/20 0.53
▸ NCOA3 Q9Y6Q9 1/20 0.53
▸ HPGD P15428 5/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ TSHR P16473 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ MRGPRX4 Q96LA9 1/20 0.51
▸ PARP1 P09874 1/20 0.46
▸ TP53 P04637 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.42
▸ OPRD1 P41143 1/20 0.41
▸ MAPT P10636 6/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368290 0.85 NPSR1 (0.50) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL11984343 0.85 HPGD (0.56) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL28857673 0.83 LMNA (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL1977403 0.83 NPSR1 (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL16812822 0.83 MRGPRX4 (0.57) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL14135378 0.83 LMNA (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL348559 0.83 LMNA (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL14114132 0.83 LMNA (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL1311028 0.83 MRGPRX4 (0.54) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL18269870 0.82 NPSR1 (0.47) LMNANPSR1PPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 — — US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 — — US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 — — US disclosed
CN-115160269-A Arylcarboxamide derivatives as positive allosteric modulators of NMDAR 北京大学 2022-10-11 — — CN disclosed
EP-3440073-B1 KINASE INHIBITORS OXULAR ACQUISITIONS LTD (GB) 2022-06-08 — — EP disclosed
EP-3978488-A1 ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION Universitetet I Oslo (NO) 2022-04-06 — — EP disclosed
EP-3978488-A1 ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION Universitetet I Oslo (NO) 2022-04-06 — — EP disclosed
CN-109952297-B Compound (I) 奥斯陆大学 2022-02-25 — — CN disclosed
CN-108299380-B Preparation method of 2, 5-disubstituted thiophene compound 中国科学院宁波材料技术与工程研究所 2021-11-19 — — CN disclosed
US-20210221791-A1 COMPOUNDS UNIVERSITETET I OSLO (NO) 2021-07-22 — — US disclosed
EP-1646608-A4 TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JE IL PHARMACEUTICAL CO LTD (KR) 2006-11-22 — — EP disclosed
CN-1826316-A Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them JE IL PHARMACEUTICAL CO LTD (KR) 2006-08-30 — — CN disclosed
EP-1646608-A1 TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JE IL Pharmaceutical Co., Ltd. (KR) 2006-04-19 — — EP disclosed
CN-1759095-A N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARM INC (US) 2006-04-12 — — CN disclosed
WO-2004113281-A1 TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JE IL PHARMACEUTICAL CO., LTD. (KR) 2004-12-29 — — WO disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 — — EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 — — US disclosed
EP-1445249-A1 NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-08-11 — — EP disclosed
WO-2004037808-A1 2 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AND ANTITUMOR COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2004-05-06 — — WO disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 LMNA 426/4885NPSR1 392/4885PPARG 4443/4885
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 LMNA 1307/4885NPSR1 617/4885PPARG 1287/4885
US-20210221791-A1 COMPOUNDS SLC30A6, SLC30A5, SLC39A11 LMNA 648/4885NPSR1 1196/4885PPARG 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.